Cefixime 400 milligram
Phase 2Small molecule
Cefixime 400 milligram is one of 12 small molecule programs targeting Syphilis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Syphilis
#DrugCompanyPhaseTrials
1Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Suprax
WWyeth-Lederle Vaccines
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Zyvox
PfizerPhase 3
Amoxil
GGlobal Antibiotics Research and Development Partnership
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Benzathine Penicillin
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Penicillin-G-Benzathine
PfizerPhase 3
Benzathine Penicilllin G
FFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Phase 3
Cefixime 400 milligram
UUniversity of California, Los Angeles
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefixime 400 milligram. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details